Literature DB >> 15579766

Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells.

Electron Kebebew1, Miao Peng, Patrick A Treseler, Orlo H Clark, Quan-Yang Duh, David Ginzinger, Richard Miner.   

Abstract

The Id (inhibitor of DNA binding) proteins are a family of helix-loop-helix (HLH) proteins (Id1, Id2, Id3, and Id4) that lack the basic domain necessary for DNA binding. The Id1 protein enhances cell proliferation and inhibits cellular differentiation in a variety of cell types. We have previously demonstrated that the Id1 gene is up-regulated in papillary and medullary thyroid cancers. In this study we characterized the expression and distribution of the Id1 protein in normal, hyperplastic, and neoplastic human thyroid tissue. We also evaluated the effect of the Id1 gene on thyroid cancer cell growth and markers of thyroid cell differentiation. We used semiquantitative immunohistochemistry to characterize Id1 protein expression in normal, hyperplastic (multinodular goiter and Graves' disease), and neoplastic thyroid tissue from 103 patients. Normal thyroid tissue had the lowest level of Id1 protein expression (P < 0.0001). Anaplastic thyroid cancer had the highest level (vs. benign and malignant thyroid tissues, P < 0.01). Id1 protein expression was higher in malignant thyroid tissue than in hyperplastic thyroid tissue (P < 0.02). We found no significant association between the level of Id1 protein expression and patient age, sex, tumor-node-metastasis stage, tumor size, primary tumor vs. lymph node metastasis, primary tumor vs. recurrent tumors, and extent of tumor differentiation. Inhibiting Id1 mRNA expression in thyroid cancer cell lines using Id1 antisense oligonucleotides resulted in growth inhibition (P < 0.03) and decreased thyroglobulin and sodium-iodine symporter mRNA expression (P < 0.02). In conclusion, Id1 is overexpressed in hyperplastic and neoplastic thyroid tissue and directly regulates the growth of thyroid cancer cells of follicular cell origin, but is not a marker of aggressive phenotype in differentiated thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579766     DOI: 10.1210/jc.2004-1234

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Role of inhibitor of DNA binding-1 protein is related to angiogenesis in the tumor advancement of uterine endometrial cancers.

Authors:  Min Khine Maw; Jiro Fujimoto; Teruhiko Tamaya
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

2.  High resolution array-CGH characterization of human stem cells using a stem cell focused microarray.

Authors:  Aaron M Elliott; Kristi A Hohenstein Elliott; Anja Kammesheidt
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

3.  TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer.

Authors:  Huiying Ma; Ye Wei; Yongmei Leng; Shichao Li; Lingling Gao; Heng Hu; Long Chen; Fei Wang; Honglei Xiao; Chouwen Zhu; Chunmin Liang
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

Review 4.  Normal vs cancer thyroid stem cells: the road to transformation.

Authors:  M Zane; E Scavo; V Catalano; M Bonanno; M Todaro; R De Maria; G Stassi
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  Effects of upregulation of Id3 in human lung adenocarcinoma cells on proliferation, apoptosis, mobility and tumorigenicity.

Authors:  F-F Chen; Y Liu; F Wang; X-J Pang; C-D Zhu; M Xu; W Yu; X-J Li
Journal:  Cancer Gene Ther       Date:  2015-09-18       Impact factor: 5.987

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Authors:  Allison B Weisbrod; Lisa Zhang; Meenu Jain; Stephanie Barak; Martha M Quezado; Electron Kebebew
Journal:  Horm Cancer       Date:  2013-01-30       Impact factor: 3.869

Review 8.  ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Authors:  Radhika Nair; Wee Siang Teo; Vivek Mittal; Alexander Swarbrick
Journal:  Mol Ther       Date:  2014-05-14       Impact factor: 11.454

9.  Anti-tumor effects of an ID antagonist with no observed acquired resistance.

Authors:  Paulina M Wojnarowicz; Marta Garcia Escolano; Yun-Han Huang; Bina Desai; Yvette Chin; Riddhi Shah; Sijia Xu; Saurabh Yadav; Sergey Yaklichkin; Ouathek Ouerfelli; Rajesh Kumar Soni; John Philip; David C Montrose; John H Healey; Vinagolu K Rajasekhar; William A Garland; Jeremy Ratiu; Yuan Zhuang; Larry Norton; Neal Rosen; Ronald C Hendrickson; Xi Kathy Zhou; Antonio Iavarone; Joan Massague; Andrew J Dannenberg; Anna Lasorella; Robert Benezra
Journal:  NPJ Breast Cancer       Date:  2021-05-24

10.  Identification of thyroid carcinoma related genes with mRMR and shortest path approaches.

Authors:  Yaping Xu; Yue Deng; Zhenhua Ji; Haibin Liu; Yueyang Liu; Hu Peng; Jian Wu; Jingping Fan
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.